Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.[L39392]
Marketing Status approved; investigational
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
TTD Drug ID D00UVA
NDC Product Code 76055-0035; 76075-103; 76075-101; 63552-009; 67262-0010; 42385-731; 76075-102; 63552-035; 54893-0037; 52076-6251; 55111-985; 11722-059
UNII 72X6E3J5AR
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
SMILES CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3) NC(=O)CN4CCOCC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Left atrial dilatation02.04.02.0250.000168%Not Available
Systolic dysfunction02.04.02.0350.000302%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000168%Not Available
Plasma cell myeloma recurrent16.23.02.006; 01.14.02.0060.001175%Not Available
Myeloma cast nephropathy20.05.03.018; 16.32.03.0240.000224%Not Available
Graft versus host disease in gastrointestinal tract12.02.09.028; 10.02.01.059; 07.11.01.0270.000112%Not Available
Administration site pain12.07.04.029; 08.02.04.0290.000246%Not Available
Application site extravasation12.07.01.049; 08.02.01.0490.000381%Not Available
Atypical haemolytic uraemic syndrome20.01.03.027; 17.02.10.027; 07.11.01.032; 01.06.02.0030.000336%Not Available
Cardiac dysfunction02.11.01.0040.000951%Not Available
Dilated cardiomyopathy02.04.01.0170.000168%Not Available
Disease complication08.01.03.0870.000806%Not Available
Drug effective for unapproved indication12.09.02.001; 08.06.01.0370.000381%Not Available
Gait inability17.02.05.069; 08.01.02.0110.000448%Not Available
Illness08.01.03.091--Not Available
Infusion site bruising08.02.05.022; 24.07.06.030; 23.03.11.034; 12.07.05.0220.000381%Not Available
Infusion site coldness12.07.05.023; 08.02.05.0230.000302%Not Available
Infusion site discomfort08.02.05.027; 12.07.05.0270.000246%Not Available
Plasma cell myeloma refractory01.14.02.008; 16.23.02.0080.000112%Not Available
Schistocytosis01.07.02.0160.000168%Not Available
Superficial vein thrombosis24.01.02.0160.000381%Not Available
Therapeutic product effect decreased08.06.01.0500.002317%Not Available
Therapeutic product effect incomplete08.06.01.0520.002843%Not Available
Therapy non-responder08.06.01.0630.004444%Not Available
Therapy partial responder08.06.01.0640.001668%Not Available
The 12th Page    First    Pre   12    Total 12 Pages